Filing Flows › Arcutis Biotherapeutics (ARQT) › Q3 2026
Arcutis Biotherapeutics (ARQT) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
Arcutis Biotherapeutics (ARQT) reported revenue of $144M for the third quarter 2026 (Q3 2026), +45% from a year earlier and +11% from the quarter before. Operating margin was 6.6%, net earnings $8.8M (6.1% of revenue).
Arcutis Biotherapeutics, Q3 2026: revenue $144M (+45% year over year), operating margin 6.6%, net earnings $8.8M, operating cash flow $18.9M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $144M | +11% | +45% |
| Operating profit | $9.4M | -43% | +11% |
| Net earnings | $8.8M | -41% | +19% |
| Operating cash flow | $18.9M | +50% | — |
| Free cash flow | $18.8M | +51% | — |
What changed
Revenue was $143.9M in Q3 2026, up 45% year over year and up 11% from the previous quarter. ZORYVE foam was the largest line at 52% of revenue. ZORYVE foam added $25.4M year over year (up 51%), 57% of the total change.
Operating profit was $9.4M, a 6.6% margin (down 2.0 points year over year). Of the extra revenue versus Q3 2025, 2% reached operating profit, below the 9% margin then. Total costs grew 48% against revenue growth of 45%. The fastest-growing cost line was SG&A (+60%). Net earnings were $8.8M, up 19% year over year. The effective tax rate was 2.2%.
Operating cash flow was $18.9M, 215% of net earnings. Non-cash charges added back $12.4M of share-based compensation. Working capital and other items used $2.3M. Capital expenditures of $97K left free cash flow of $18.8M.
Questions
What was Arcutis Biotherapeutics' revenue in the third quarter 2026?
Arcutis Biotherapeutics (ARQT) reported revenue of $144M for the third quarter 2026 (Q3 2026), +45% from a year earlier and +11% from the quarter before.
Was Arcutis Biotherapeutics profitable in the third quarter 2026?
Operating profit was $9.4M (6.6% of revenue) and net earnings $8.8M.